
Calliditas Therapeutics AB (publ) CALT
Quarterly report 2022-Q2
added 08-19-2022
Calliditas Therapeutics AB (publ) Income Statement 2011-2025 | CALT
Annual Income Statement Calliditas Therapeutics AB (publ)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
966 M | 606 M | - | - | 106 M | - | - | - | - | - | - |
Shares |
50.8 M | 22.4 M | - | - | 33.2 M | - | - | - | - | - | - |
Historical Prices |
19.7 | 28.1 | - | - | - | - | - | - | - | - | - |
Net Income |
-510 M | -433 M | -32.6 M | -132 M | -86.8 M | -56.9 M | -51 M | - | - | - | - |
Revenue |
- | 874 K | 185 M | - | - | - | - | - | - | - | - |
Operating Income |
-524 M | -380 M | -28 M | -132 M | - | - | - | - | - | - | - |
EBITDA |
-524 M | -377 M | -26.1 M | -133 M | -84.6 M | -56.4 M | -51.3 M | - | - | - | - |
Operating Expenses |
- | - | 213 M | 133 M | 84.7 M | 56.5 M | 51.4 M | - | - | - | - |
General and Administrative Expenses |
390 M | 142 M | 62.9 M | 133 M | 64 M | 41.3 M | 43 M | - | - | - | - |
All numbers in SEK currency
Quarterly Income Statement Calliditas Therapeutics AB (publ)
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | 52.4 M | - | - | 49.9 M | 49.9 M | - | - | 40.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
- | - | - | -207 M | - | - | -163 M | -133 M | - | - | -61.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | 614 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | 49.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | - | -208 M | - | - | -159 M | -151 M | - | - | -66.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | -208 M | - | - | -159 M | -151 M | - | - | -66.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | - | 84.4 M | - | - | - | 18.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in SEK currency
The income statement is one of the three key financial reports of a company Calliditas Therapeutics AB (publ) (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.21 | 1.68 % | $ 130 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Cronos Group
CRON
|
$ 2.67 | 0.19 % | $ 1.39 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | ||
|
Aurora Cannabis
ACB
|
$ 4.35 | -3.12 % | $ 86.3 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | ||
|
Emergent BioSolutions
EBS
|
$ 12.29 | -1.09 % | $ 629 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.57 | -0.12 % | $ 2.05 B | ||
|
Evolus
EOLS
|
$ 6.66 | -3.55 % | $ 413 M | ||
|
Harrow Health
HROW
|
$ 50.7 | 1.22 % | $ 1.65 B | ||
|
China Pharma Holdings
CPHI
|
$ 1.27 | -1.32 % | $ 22.2 M | ||
|
OrganiGram Holdings
OGI
|
$ 1.7 | -5.31 % | $ 402 M | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | ||
|
Organogenesis Holdings
ORGO
|
$ 5.19 | -1.71 % | $ 683 M | ||
|
Bausch Health Companies
BHC
|
$ 7.16 | -0.56 % | $ 2.61 B | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.66 | 0.83 % | $ 4.54 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 4.01 | -2.55 % | $ 56.4 M | ||
|
Rockwell Medical
RMTI
|
$ 0.8 | -7.01 % | $ 18.7 M | ||
|
Pacira BioSciences
PCRX
|
$ 26.17 | -1.3 % | $ 1.21 B | ||
|
Sundial Growers
SNDL
|
$ 1.71 | -1.16 % | $ 3.37 M | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
Veru
VERU
|
$ 2.22 | -7.71 % | $ 299 M | ||
|
Perrigo Company plc
PRGO
|
$ 13.94 | 0.87 % | $ 1.92 B | ||
|
ProPhase Labs
PRPH
|
$ 0.45 | -14.17 % | $ 7.13 M | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
cbdMD
YCBD
|
$ 1.43 | -15.88 % | $ 6.17 M | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
$ 4.43 | -1.77 % | $ 133 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
$ 9.56 | -3.82 % | $ 679 M | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
$ 5.63 | -3.68 % | $ 230 M | ||
|
SCYNEXIS
SCYX
|
$ 0.63 | 6.75 % | $ 30.1 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Tilray
TLRY
|
$ 9.32 | -2.87 % | $ 5.76 B | ||
|
TherapeuticsMD
TXMD
|
$ 1.68 | -3.43 % | $ 17.5 M |